Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Michele C. Gornick, PhD, MA and Brian J. Zikmund-Fisher, PhD, MA
How information is provided can change a choice. Decision science helps reveal affective forecasting errors and can generate choices congruent with patients’ and families’ values.
AMA J Ethics. 2019;21(10):E906-912. doi:
10.1001/amajethics.2019.906.
Decision making in health care demands that we balance multiple considerations, like quality of life, statistics, and how different options could affect others. Dr Brian Zikmund-Fisher shares his own experience as a patient and explains how decision science can help us navigate ethically complex health decisions.
AI might improve patient-clinician relationships, but various underlying assumptions will need to be addressed to bring these potential benefits to fruition.
AMA J Ethics. 2020;22(5):E395-400. doi:
10.1001/amajethics.2020.395.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Professor john powell joins us for this special edition of Ethics Talk to discuss how a lens of “othering and belonging” can help us navigate our obligations to and relationships with each other, especially during this COVID-19 pandemic.